ATE514709T1 - Modifizierte clostridientoxine mit erhöhter targeting-kapazität für endogene clostridientoxin-rezeptorsysteme - Google Patents

Modifizierte clostridientoxine mit erhöhter targeting-kapazität für endogene clostridientoxin-rezeptorsysteme

Info

Publication number
ATE514709T1
ATE514709T1 AT06738062T AT06738062T ATE514709T1 AT E514709 T1 ATE514709 T1 AT E514709T1 AT 06738062 T AT06738062 T AT 06738062T AT 06738062 T AT06738062 T AT 06738062T AT E514709 T1 ATE514709 T1 AT E514709T1
Authority
AT
Austria
Prior art keywords
clostridial toxin
endogene
modified
toxin receptor
receptor systems
Prior art date
Application number
AT06738062T
Other languages
English (en)
Inventor
Lance Steward
Ester Fernandez-Salas
Joseph Francis
Shengwen Li
Marcella Gilmore
Kei Aoki
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE514709T1 publication Critical patent/ATE514709T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT06738062T 2005-03-15 2006-03-14 Modifizierte clostridientoxine mit erhöhter targeting-kapazität für endogene clostridientoxin-rezeptorsysteme ATE514709T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66215105P 2005-03-15 2005-03-15
US66195305P 2005-03-15 2005-03-15
PCT/US2006/008956 WO2006101809A1 (en) 2005-03-15 2006-03-14 Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems

Publications (1)

Publication Number Publication Date
ATE514709T1 true ATE514709T1 (de) 2011-07-15

Family

ID=36648754

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06738062T ATE514709T1 (de) 2005-03-15 2006-03-14 Modifizierte clostridientoxine mit erhöhter targeting-kapazität für endogene clostridientoxin-rezeptorsysteme

Country Status (7)

Country Link
US (4) US8128940B2 (de)
EP (3) EP2316847A3 (de)
JP (2) JP2008535486A (de)
AT (1) ATE514709T1 (de)
AU (3) AU2006227816B2 (de)
CA (2) CA2601577A1 (de)
WO (2) WO2006101809A1 (de)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
ATE348178T1 (de) * 1999-08-25 2007-01-15 Allergan Inc Aktivierbare rekombinante neurotoxine
US20090018081A1 (en) * 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
DE602005011458D1 (de) * 2004-09-01 2009-01-15 Allergan Inc Abbaubare clostridientoxine
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
GB0426397D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8021859B2 (en) * 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
AU2006227816B2 (en) 2005-03-15 2012-04-05 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
ATE518882T1 (de) * 2005-09-19 2011-08-15 Allergan Inc Mit clostridientoxin aktivierbare clostridientoxine
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
CN103126971A (zh) * 2005-11-17 2013-06-05 雷文斯治疗公司 减少非毒素蛋白质的肉毒杆菌毒素组合物和其局部施用及透皮递送方法
ATE458000T1 (de) * 2005-11-18 2010-03-15 Dabur Pharma Ltd Zielgerichtete fusionsproteine für die krebstherapie
EP2001902B1 (de) * 2006-03-14 2013-03-27 Allergan, Inc. Modifizierte clostridiale toxine mit geänderten targeting-fähigkeiten für die target-zellen von clostridialem toxin
WO2008105901A2 (en) * 2006-07-11 2008-09-04 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
AU2007272515B2 (en) 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
WO2008008805A2 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
US20090104160A1 (en) * 2007-02-01 2009-04-23 Moraga Biotechnology Corporation Mobilization of Stem Cells After Trauma and Methods Therefor
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
US8486422B2 (en) * 2007-07-26 2013-07-16 Allergan, Inc. Methods of activating clostridial toxins
US10466245B2 (en) 2008-02-20 2019-11-05 The Secretary Of State For Health Covalently linked thermostable kinase for decontamination process validation
GB0803068D0 (en) 2008-02-20 2008-03-26 Health Prot Agency Cross-linked biological indicator
PT2271670E (pt) 2008-03-14 2014-11-28 Allergan Inc Ensaio imunobaseado da atividade do serotipo a da toxina botulínica
KR101604515B1 (ko) * 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
CA2727082C (en) * 2008-06-12 2019-02-26 Syntaxin Limited Fusion proteins for use in suppression of acromegaly
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
CN102083451A (zh) * 2008-06-12 2011-06-01 赛恩泰新公司 癌症的抑制
US20100034853A1 (en) * 2008-08-05 2010-02-11 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type B
US20100034854A1 (en) * 2008-08-05 2010-02-11 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type B (150 KD)
KR20110060903A (ko) * 2008-08-29 2011-06-08 메르츠 파마 게엠베하 운트 코. 카가아 지속성이 변경된 클로스트리듐 신경독
US20100112006A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type B (150 kD)
WO2010051039A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type b
GB0820970D0 (en) * 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
CN105833254A (zh) 2008-12-10 2016-08-10 阿勒根公司 梭菌毒素药物组合物
BRPI1008940A2 (pt) 2009-03-13 2020-10-27 Allergan, Inc. linhagem de célula clonal estabelecida suscetível à intoxicação por bont/a
AU2010236613B2 (en) * 2009-04-14 2016-07-07 Mcw Research Foundation, Inc. Engineered botulinum neurotoxin
US20100303789A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases
US20100303791A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
US20100303756A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Interleukin Retargeted Endopepidases
US20100303788A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
US20100303798A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Neurotrophin Retargeted Endopepidases
US20100303794A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
US20100303783A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
US20100303757A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
CN102573876A (zh) * 2009-08-14 2012-07-11 阿勒根公司 使用甘丙肽再靶向内肽酶治疗癌症的方法
CN102574899A (zh) * 2009-08-14 2012-07-11 阿勒根公司 使用胰高血糖素样激素再靶向内肽酶治疗癌症的方法
CA2771154A1 (en) 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using opioid retargeted endpeptidases
EP2464366A2 (de) * 2009-08-14 2012-06-20 Allergan, Inc. Verfahren zur behandlung von krebs mit wachstumsfaktor-retargetierten endopeptidasen
AU2010282276A1 (en) 2009-08-14 2012-03-15 Allergan, Inc. Methods of treating cancer using neurotrophin retargeted endopeptidases
WO2011020114A2 (en) 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using tachykinin retargeted endopeptidases
CA2782465C (en) * 2009-12-02 2018-03-20 Zymeworks Inc. Combined on-lattice/off-lattice optimization method for rigid body docking
SG181772A1 (en) * 2009-12-16 2012-07-30 Allergan Inc Modified clostridial toxins comprising an integrated protease cleavage site-binding domain
US20130245227A1 (en) * 2010-01-15 2013-09-19 Allergan, Inc. Methods of activating clostridial toxins
JP5956350B2 (ja) * 2010-01-25 2016-07-27 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 単鎖タンパク質をそれらの２鎖形態に細胞内変換する方法
EP2650003B1 (de) 2010-05-20 2016-07-27 Allergan, Inc. Abbaubare clostridientoxine
CN103068837B (zh) * 2010-05-28 2015-06-24 斯匹遐生物技术公司 嵌合momp抗原、方法和使用
WO2011162558A2 (ko) * 2010-06-24 2011-12-29 (주)지노믹트리 아데닐레이트 싸이클라제 활성화 폴리펩타이드 1 (뇌하수체)의 유전자를 함유하는 자궁경부암세포의 증식 억제용 재조합벡터 및 자궁경부암 치료용 약학 조성물
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
US20130261062A1 (en) 2010-10-14 2013-10-03 Allergan, Inc. Targeted delivery of targeted exocytosis modulators to the sphenopalatine ganglion for treatment of headache disorders
WO2012112420A1 (en) * 2011-02-14 2012-08-23 Allergan, Inc. Treatments using psma ligand endopeptidases
WO2012112432A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Methods of inhibiting aberrant blood vessel formation using opioid retargeted endopeptidases
WO2012112422A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using growth factor retargeted endopeptidases
WO2012112434A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using retargeted endopeptidases
US20120207734A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Methods of Inhibiting Aberrant Blood Vessel Formation Using Opioid Retargeted Endpeptidases
US20120244188A1 (en) * 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20120251574A1 (en) * 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120251575A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
US20120251573A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Neuroendocrine Disorders
US20120251515A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Cosmesis Disorders
WO2012135304A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Vagal nerve-based disorders
US20120251518A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20120251519A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Smooth Muscle Disorders
WO2012174123A1 (en) 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US20130171122A1 (en) * 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
EP2798077A2 (de) 2011-12-31 2014-11-05 Allergan, Inc. Hochempfindlicher zellbasierter test für den nachweis der anwesenheit von aktivem botulinum-neurotoxin-serotyp-a
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
EP2819688A4 (de) 2012-02-15 2015-10-28 Aileron Therapeutics Inc Triazol- und thioethervernetzte peptidomimetische makrozyklen
UA116985C2 (uk) 2012-05-30 2018-06-11 Президент Енд Феллоуз Оф Гарвард Колледж Рекомбінантний ботулінічний нейротоксин
US9005628B2 (en) * 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
WO2014079495A1 (en) * 2012-11-21 2014-05-30 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
WO2014100019A1 (en) 2012-12-18 2014-06-26 Allergan, Inc. Prophylactic treatment of herpes recurrence
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
LT3030905T (lt) 2013-08-09 2018-01-25 Biomadison, Inc. Padidinto jautrumo botulino toksino tyrimas
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
US10226529B2 (en) * 2014-06-04 2019-03-12 Osaka University Adjuvant for mucosal vaccine
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
EP3197478A4 (de) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetische makrozyklen und verwendungen davon
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
PT3274364T (pt) 2015-03-26 2021-11-05 Harvard College Neurotoxina botulínica manipulada
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
SG11201809903WA (en) * 2016-05-16 2018-12-28 Harvard College Method for purification and activation of botulinum neurotoxin
EP3481852B1 (de) * 2016-07-08 2022-12-07 Children's Medical Center Corporation Neuartiges botulinumneurotoxin und dessen derivate
EP3504226A1 (de) 2016-08-24 2019-07-03 President and Fellows of Harvard College Manipuliertes botulinumneurotoxin
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
TW201814045A (zh) 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 製造雙鏈梭狀芽孢桿菌神經毒素之方法
JP7118055B2 (ja) 2016-09-29 2022-08-15 イプセン バイオファーム リミテッド ハイブリッド神経毒
EP3312290A1 (de) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Zellulärer vamp-spaltungstest
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CA3189470A1 (en) 2020-08-21 2022-02-24 Yves SABBAGH Fgfr3 antibodies and methods of use
WO2022202785A1 (ja) * 2021-03-22 2022-09-29 美智子 甲賀 ポリペプチド並びにそれを含む細胞融合剤及びがん治療用医薬組成物

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
WO1989004839A1 (en) * 1987-11-24 1989-06-01 Genetics Institute, Inc. Improved ricin molecules and ricin toxin conjugates
AU7492291A (en) 1990-02-26 1991-09-18 Board Of Trustees Of The Leland Stanford Junior University Identification and expression of insect steroid receptor dna sequences
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
EP0745121B1 (de) 1992-05-14 2007-06-20 Baylor College Of Medicine Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
DE122009000066I2 (de) * 1993-06-10 2010-12-30 Allergan Inc Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US20040126396A1 (en) 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
US5714469A (en) 1994-09-01 1998-02-03 Smithkline Beecham Corporation Method of treating sepsis
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US5939070A (en) * 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
WO2000023427A1 (de) 1998-10-20 2000-04-27 Basf Aktiengesellschaft Verfahren zur herstellung von gegebenenfalls substituierten 1-methyl-6-halogenalkyluracilen
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
US6776990B2 (en) * 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6767544B2 (en) 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US6358917B1 (en) 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US20080032931A1 (en) 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
ATE348178T1 (de) 1999-08-25 2007-01-15 Allergan Inc Aktivierbare rekombinante neurotoxine
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
US20030180289A1 (en) 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6261572B1 (en) 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6500436B2 (en) * 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6524580B1 (en) 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6565870B1 (en) 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US20030219462A1 (en) 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6827931B1 (en) 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US6921538B2 (en) 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US20040072276A1 (en) 2002-05-10 2004-04-15 Direvo BioTech AG. Process for generating sequence-specific proteases by directed evolution and use thereof
CA2501856A1 (en) 2002-10-15 2004-04-29 Allergan, Inc. Botulinum toxin dental therapies and procedures
US7238357B2 (en) 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US20040115727A1 (en) 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
US8071550B2 (en) 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
US6838434B2 (en) 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US8231728B2 (en) 2003-07-15 2012-07-31 Nippon Mining & Metals Co., Ltd. Epitaxial growth process
GB2405297B (en) 2003-08-20 2006-12-20 Vodafone Plc Data distribution
GB0321344D0 (en) 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
NZ545393A (en) 2003-09-19 2009-10-30 Wisconsin Alumni Res Found 2-Alkylidene-19-nor-vitamin D derivatives for the treatment of osteopenia or male osteoporosis
ES2374822T3 (es) 2004-02-24 2012-02-22 Allergan, Inc. Ensayo de selección de toxinas botul�?nicas.
AU2005265093A1 (en) 2004-06-18 2006-01-26 Wyeth Processes for preparing 6-alkyl-5-arylsulfonyl- dihydrophenanthridines
WO2006011966A1 (en) 2004-06-30 2006-02-02 Allergan, Inc. Optimizing expression of active botulinum toxin type e
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
JP3773058B2 (ja) 2004-07-20 2006-05-10 コナミ株式会社 ゲーム装置、ゲーム装置の制御方法及びプログラム
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
US7567546B2 (en) 2004-09-09 2009-07-28 Panasonic Corporation Transmitter device, bridge device, and receiver device, and network system including the devices
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
AU2005311098B2 (en) 2004-12-01 2011-08-11 Allergan, Inc. Non-cytotoxic protein conjugates
AU2005311086B2 (en) 2004-12-01 2012-03-29 Allergan, Inc. Fusion proteins
AU2006227816B2 (en) * 2005-03-15 2012-04-05 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
US8273865B2 (en) * 2006-03-15 2012-09-25 Allergan, Inc. Multivalent clostridial toxins
KR100677871B1 (ko) 2006-09-11 2007-02-02 주식회사 메가젠 골충진재 성형 장치 및 골충진재 성형 방법
US7958590B2 (en) 2006-12-29 2011-06-14 Kimberly-Clark Worldwide, Inc. Cleaning tool handle for use with a disposable toilet brush

Also Published As

Publication number Publication date
AU2012203366A1 (en) 2012-06-28
US20080096248A1 (en) 2008-04-24
US8460682B2 (en) 2013-06-11
AU2006227816A1 (en) 2006-09-28
EP1871789B1 (de) 2013-11-06
CA2601592A1 (en) 2006-09-28
US20120052548A1 (en) 2012-03-01
JP2008532549A (ja) 2008-08-21
EP2316847A2 (de) 2011-05-04
JP2008535486A (ja) 2008-09-04
US20120178140A1 (en) 2012-07-12
AU2006225116A1 (en) 2006-09-21
EP1861419B1 (de) 2011-06-29
US8128940B2 (en) 2012-03-06
WO2006101809A1 (en) 2006-09-28
WO2006099590A2 (en) 2006-09-21
US8052979B2 (en) 2011-11-08
AU2006225116B2 (en) 2012-04-19
EP1861419A1 (de) 2007-12-05
EP2316847A3 (de) 2012-01-18
US8623999B2 (en) 2014-01-07
EP1871789A2 (de) 2008-01-02
WO2006099590A3 (en) 2007-03-15
CA2601577A1 (en) 2006-09-21
AU2006227816B2 (en) 2012-04-05
US20080161543A1 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
ATE514709T1 (de) Modifizierte clostridientoxine mit erhöhter targeting-kapazität für endogene clostridientoxin-rezeptorsysteme
DK2154151T3 (da) Clostridiumtoksinaktiverbare clostridiumtoksiner
WO2008008803A3 (en) Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
ZA202209226B (en) Non-neuronal snare-cleaving botulinum neurotoxins
WO2008008805A3 (en) Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
WO2008105901A3 (en) Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
EP4588519A3 (de) Immunobasierte assays für botulinumtoxin-serotyp-a-aktivität
WO2011142783A3 (en) Modified clostridial toxins comprising an integrated protease cleavage site-binding domain
SG159458A1 (en) Novel immunoglobulin-binding proteins with improved specificity
WO2010014854A3 (en) Antibodies that neutralize botulinum neurotoxins
ATE416191T1 (de) Abbaubare clostridientoxine
PL2318032T3 (pl) Zastosowanie hsp70 jako regulatora aktywności enzymatycznej
LT2857418T (lt) Antikūnai prieš clostridium difficile toksinus ir jų panaudojimas
CY1114954T1 (el) Νεα μη-κυτταροτοξικα συζευγματα πρωτεϊνης
WO2006059113A3 (en) Fusion proteins comprising a non-cytotoxic protease, a targeting moiety, a protease cleavage site and a translocation domain
WO2011126811A3 (en) High level expression of recombinant toxin proteins
WO2010053606A3 (en) Small-molecule inhibitors of protein synthesis inactivating toxins
DK1920248T3 (da) Clostridialt-toksin-aktivitetsassays
WO2010019257A3 (en) Prodrug activation in cancer cells using molecular switches
WO2006135793A3 (en) Protein engineering with analogous contact environments
WO2007143004A3 (en) Methods, compositions, and kits for treating shiga toxin associated conditions
WO2008145013A8 (zh) 包含cd13靶向肽和力达霉素的融合蛋白
WO2006093997A3 (en) Electrochemically and optically monitoring cleaving enzyme activity
WO2009009800A3 (en) Antitoxin destabilization technology
BRPI0509478A (pt) tratamento de ferida por pressão

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties